Welcome to the OCTRU Blog

A Blog on all aspects of clinical trials - maintained by the Oxford Clinical Trials Unit (OCTRU)

Displaying 86 - 90 of 106

Oesophageal cancer: is there a small group of responding patients that can be identified who will benefit from gefitinib treatment?

The primary results of a randomised multicentre parallel group placebo-controlled trial of gefitinib versus placebo in oesophageal cancer patients progressing after chemotherapy was published onlin

Pages